Literature DB >> 3291085

Cimetidine responders in non-ulcer dyspepsia.

T Johannessen1, U Fjøsne, P M Kleveland, T Halvorsen, P Kristensen, I Løge, P E Hafstad, P Sandbakken, H Petersen.   

Abstract

The effect of cimetidine and placebo was examined in 123 patients with non-ulcer dyspepsia (NUD) by means of a 12-day multi-crossover model with 5 regular interchanges between cimetidine and placebo. The evaluation of effect in individual patients was based on the number of times cimetidine was associated with less symptoms than the preceding or following placebo period. If cimetidine had no effect, the probability of being defined as a cimetidine responder was 25%. In general, cimetidine was associated with less symptoms than placebo (p less than 0.0001). Forty patients were identified as cimetidine responders (R) and the remaining patients were termed non-responders (NR). Symptoms compatible with gastroesophageal reflux were significantly more frequent in R than in NR, whereas the opposite was true for symptoms of the irritable colon syndrome. The ability of symptoms selected by stepwise logistic regression to predict response to cimetidine showed at best a sensitivity of 75% and a specificity of about 65%. No differences were found between R and NR with regard to acid secretion, endoscopic and histologic findings, or the result of an acid perfusion test. The present study supports the existence of a subgroup of cimetidine responders among patients with NUD characterized by symptoms suggestive of gastroesophageal reflux disease in the absence of confirmatory objective evidence.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291085     DOI: 10.3109/00365528809093874

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  12 in total

1.  Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus".

Authors:  R G Watson; T C Tham; B T Johnston; N I McDougall
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

2.  Controlled trials in single subjects. 1. Value in clinical medicine.

Authors:  T Johannessen
Journal:  BMJ       Date:  1991-07-20

Review 3.  Formulary management of drugs for cancer-associated hypercalcaemia.

Authors:  S J Gallacher
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

4.  Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.

Authors:  R F Tasch; R Goeree; C J Henke; B J O'Brien
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

5.  Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

Authors:  R H Hunt
Journal:  CMAJ       Date:  1996-01-01       Impact factor: 8.262

Review 6.  H(2) receptor antagonists and prokinetics in dyspepsia: a critical review.

Authors:  Peter Bytzer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

7.  Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study.

Authors:  J Y Kang; H H Tay; A Wee; R Guan; M V Math; I Yap
Journal:  Gut       Date:  1990-04       Impact factor: 23.059

8.  Long term acid suppressing treatment in general practice.

Authors:  S D Ryder; S O'Reilly; R J Miller; J Ross; M R Jacyna; A J Levi
Journal:  BMJ       Date:  1994-03-26

Review 9.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

10.  Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration.

Authors:  M M Morales Suárez-Varela; M A Pérez-Benajas; V J Girbes Pelechano; A Llopis-González
Journal:  Eur J Epidemiol       Date:  1998-06       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.